Phathom Pharmaceuticals (NasdaqGS:PHAT) Q4 2025 Earnings call February 26, 2026 08:00 AM ET Company ParticipantsAnnabel Samimy - Managing Director of BioPharma and BiotechnologyAnthea Li - Senior Associate in Biotechnology Equity ResearchEric Sciorilli - Head of Investor RelationsMartin Auster - Managing DirectorMin Lee - Biotech Equity Research AssociateSanjeev Narula - Chief Financial and Business OfficerSteven Basta - President and CEOConference Call ParticipantsChase Knickerbocker - Senior Equity Resear ...

Akebia Therapeutics (NasdaqCM:AKBA) Q4 2025 Earnings call February 26, 2026 08:00 AM ET Company ParticipantsAshleigh Acker - Biotechnology Equity Research AssociateErik Ostrowski - CFO and Chief Business OfficerJohn Butler - President, CEO, and DirectorMercedes Carrasco - Senior Director of Investor and Corporate CommunicationsNicholas Grund - Chief Commercial OfficerSteven Burke - Chief Medical OfficerConference Call ParticipantsJulian Harrison - Managing Director and Biotechnology AnalystMichael Cherny - ...

Akebia Therapeutics (NasdaqCM:AKBA) Q4 2025 Earnings call February 26, 2026 08:00 AM ET Company ParticipantsErik Ostrowski - CFO and Chief Business OfficerJohn Butler - President, CEO, and DirectorMercedes Carrasco - Senior Director of Investor and Corporate CommunicationsNicholas Grund - Chief Commercial OfficerSteven K. Burke - Senior Vice President, Chief Research and Development OfficerConference Call ParticipantsJulian Harrison - Managing Director and Biotechnology AnalystManagi Nassar - Senior Equity ...

BeOne Medicines (NasdaqGS:BGNE) Q4 2025 Earnings call February 26, 2026 08:00 AM ET Company ParticipantsAaron Rosenberg - CFOAmit Aggarwal - Chief Medical Officer of HematologyDan Maller - VP of Investor RelationsJohn V. Oyler - Co-Founder, Chairman and CEOLai Wang - President and Global Head of Research & DevelopmentMark Lanasa - SVP and Chief Medical OfficerMatt Shaulis - General Manager of North AmericaSean Laaman - Executive DirectorXiaobin Wu - President and COOZhihong Chen - Managing DirectorNone - Co ...

Intellia Therapeutics (NasdaqGM:NTLA) Q4 2025 Earnings call February 26, 2026 08:00 AM ET Company ParticipantsEdward Dulac - EVP and CFOJason Fredette - Vice President of Investor Relations and Corporate CommunicationsJohn Leonard - President and CEOLidiya Rizova - Associate, Equity ResearchNone - Company RepresentativeConference Call ParticipantsAlec Stranahan - Senior Analyst, Equity ResearchBrian Cheng - Executive Director and Senior Biotech AnalystJack Allen - Senior Research AnalystJonathan Miller - An ...

Rhythm Pharmaceuticals (NasdaqGM:RYTM) Q4 2025 Earnings call February 26, 2026 08:00 AM ET Company ParticipantsCorinne Johnson - Managing DirectorDave Connolly - Head of Investor Relations and Corporate CommunicationsDavid Meeker - Chairman, CEO, and PresidentDerek Archila - Managing Director and Co-Head of Therapeutics ResearchHunter Smith - CFOJennifer Lee - EVP and Head of North AmericaJon Wolleben - Managing DirectorTazeen Ahmad - Managing DirectorYann Mazabraud - EVP and Head of InternationalConference ...

Rhythm Pharmaceuticals (NasdaqGM:RYTM) Q4 2025 Earnings call February 26, 2026 08:00 AM ET Company ParticipantsCorinne Johnson - Managing DirectorDave Connolly - Head of Investor Relations and Corporate CommunicationsDavid Meeker - Chairman, CEO, and PresidentDerek Archila - Managing Director and Co-Head of Therapeutics ResearchHunter Smith - CFOJennifer Lee - EVP and Head of North AmericaJon Wolleben - Managing DirectorTazeen Ahmad - Managing DirectorYann Mazabraud - EVP and Head of InternationalConference ...

Zai Lab (NasdaqGM:ZLAB) Q4 2025 Earnings call February 26, 2026 08:00 AM ET Company ParticipantsChristine Chiou - SVP of Investor RelationsHaichong Lin - AssociateJonathan Chang - Senior Managing Director of Emerging OncologyJosh Smiley - President and COOLi Watsek - DirectorMichael Yee - Global Head of Biotechnology ResearchRafael Amado - President and Head of Global Research and DevelopmentSamantha Du - Founder, Chairperson, and CEOYajing Chen - CFOConference Call ParticipantsAnupam Rama - Managing Direct ...

Argenx SE (NASDAQ:ARGX) on Thursday announced positive topline results from the Phase 3 ADAPT OCULUS study evaluating VYVGART in adults with ocular myasthenia gravis (oMG).It is an autoimmune disorder where antibodies disrupt nerve-muscle communication, causing variable, fatiguing weakness of eye muscles and eyelids (ptosis) and double vision (diplopia).The study met its primary endpoint, demonstrating statistically significant improvement in patient-reported outcomes.Argenx Says Vyvgart Improves Double Vis ...

Intellia Therapeutics (NasdaqGM:NTLA) Q4 2025 Earnings call February 26, 2026 08:00 AM ET Speaker11Hello, and welcome to Intellia Therapeutics' fourth quarter and full year 2025 conference call. My name is Drew, and I will be your conference operator today. Please be advised that today's call is being recorded. I will now turn the call over to Jason Fredette, Vice President of Investor Relations and Corporate Communications at Intellia. Please proceed.Speaker4Thank you, operator. Hello, everyone. Earlier th ...